Top

Supportive Care in Cancer

Published in:

01-01-2017 | Special Article

2016 updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy

Authors: L. Lee Dupuis, Joseph A. Roscoe, Ian Olver, Matti Aapro, Alexander Molassiotis

Published in: Supportive Care in Cancer | Issue 1/2017

Abstract

Purpose

We aimed to update the 2011 recommendations for the prevention and treatment of anticipatory nausea and vomiting in children and adults receiving chemotherapy.

Methods

The original systematic literature search was updated. Randomized studies were included in the evidence to support this guideline if they as follows: were primary studies published in a journal in full text (i.e., abstracts, letters, book chapters, and dissertations were excluded); published in English; evaluated an intervention for the prevention or treatment of anticipatory nausea and vomiting; reported the proportion of patients experiencing complete control of anticipatory nausea and vomiting consistently and; included at least ten participants per study arm for comparative studies and at least ten participants overall for noncomparative studies.

Results

Eighty-eight new citations were identified. Of these, nine were brought to full-text screening; none met inclusion criteria. The guideline panel continues to recommend that anticipatory nausea and vomiting are best prevented through optimization of acute and delayed phase chemotherapy-induced nausea and vomiting control. Benzodiazepines and behavioral therapies, in particular progressive muscle relaxation training, systematic desensitization and hypnosis, continue to be recommended for the treatment of anticipatory nausea and vomiting.

Conclusions

No new information regarding interventions aimed at treating or preventing ANV that met criteria for inclusion in this systematic review was identified. The 2015 MASCC recommendations affirm the content of the 2009 MASCC recommendations for the prevention and treatment of anticipatory nausea and vomiting.

Roscoe J, Morrow G, Aapro M, Molassiotis A, Olver I (2011) Anticipatory nausea and vomiting. Support Care Cancer 19:1533–1538CrossRefPubMed

Watson M, Meyer L, Thomson A, Osofsky S (1998) Psychological factors predicting nausea and vomiting in breast cancer patients on chemotherapy. Eur J Cancer 34(6):831–837CrossRefPubMed

Tyc VL, Mulhern RK, Barclay DR, Smith BF, Bieberich AA (1997) Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy. J Pediatr Psychol 22(1):45–58CrossRefPubMed

Tyc VL, Mulhern RK, Bieberich AA (1997) Anticipatory nausea and vomiting in pediatric cancer patients: an analysis of conditioning and coping variables. J Dev Behav Pediatr 18(1):27–33CrossRefPubMed

Chan A, Kim HK, Hsieh RK, Yu S, de Lima LG, Su WC, Banos A, Bhatia S, Burke TA, Keefe DMK (2014) Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice-a longitudinal analysis. Support Care Cancer 23(1):283–291. doi:10.1007/s00520-014-2375-0 CrossRefPubMed

Molassiotis A, Lee P, Burke T, Dicato M, Gascon P, Roila F, Aapro M (2016) Anticipatory nausea, risk factors and its impact on chemotherapy-related nausea and vomiting: results from the PEER study. J Pain Symptom Manage in press

Akechi T, Okuyama T, Endo C, Sagawa R, Uchida M, Nakaguchi T, Sakamoto M, Komatsu H, Ueda R, Wada M, Furukawa T (2010) Anticipatory nausea among ambulatory cancer patients undergoing chemotherapy: prevalence, associated factors, and impact on quality of life. Cancer Sci 101(12):2596–2600CrossRefPubMed

Kamen C, Tejani MA, Chandwani K, Janelsins M, Peoples AR, Roscoe JA, Morrow GR (2014) Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 722(1):172–179. doi:10.1016/j.ejphar.2013.09.071 CrossRefPubMed

Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa S, Isambert N, Burke T, Gu A, Roila F (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47(5):839–848. doi:10.1016/j.jpainsymman.2013.06.012 CrossRefPubMed

10.

Rock EM, Limebeer CL, Parker LA (2014) Anticipatory nausea in animal models: a review of potential novel therapeutic treatments. Exp Brain Res 232(8):2511–2534. doi:10.1007/s00221-014-3942-9 CrossRefPubMed

11.

Stockhorst U, Hall G, Enck P, Klosterhalfen S (2014) Effects of overshadowing on conditioned and unconditioned nausea in a rotation paradigm with humans. Exp Brain Res 232(8):2651–2664. doi:10.1007/s00221-014-3998-6 CrossRefPubMed

12.

Stockhorst U, Wiener J, Klosterhalfen S, Klosterhafner W, Aul C, Steingruber H (1998) Effects of overshadowing on conditioned nausea in cancer patients: an experimental study. Physiol Behav 64:743–753CrossRefPubMed

13.

Dupuis LL, Robinson PD, Boodhan S, Holdsworth M, Portwine C, Gibson P, Phillips R, Maan C, Stefin N, Sung L (2014) Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. Pediatr Blood Cancer 61(8):1506–1512. doi:10.1002/pbc.25063 CrossRefPubMed

14.

Razavi D, Delvaux N, Farvacques C, De Brier F, Van Heer C, Kaufman L, Derde MP, Beauduin M, Piccart M (1993) Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 11(7):1384–1390PubMed

15.

Raynov J, Stanchev R, Radinov A, Kancheva T (1999) Anticipatory emesis in cancer patients, treated with high - and moderately emetogenic chemotherapy. Arch Oncol 7(4):145–148

16.

Malik IA, Khan WA, Qazilbash M, Ata E, Butt A, Khan MA (1995) Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 18(2):170–175CrossRefPubMed

17.

Jacknow DS, Tschann JM, Link MP, Boyce WT (1994) Hypnosis in the prevention of chemotherapy-related nausea and vomiting in children: a prospective study. J Dev Behav Pediatr 15(4):258–264CrossRefPubMed

18.

Zeltzer LK, Dolgin MJ, LeBaron S, LeBaron C (1991) A randomized, controlled study of behavioral intervention for chemotherapy distress in children with cancer. Pediatrics 88(1):34–42PubMed

19.

Lerman C, Rimer B, Blumberg B, Cristinzio S, Engstrom PF, MacElwee N, O'Connor K, Seay J (1990) Effects of coping style and relaxation on cancer chemotherapy side effects and emotional responses. Cancer Nurs 13(5):308–315CrossRefPubMed

20.

Marchioro G, Azzarello G, Viviani F, Barbato F, Pavanetto M, Rosetti F, Pappagallo GL, Vinante O (2000) Hypnosis in the treatment of anticipatory nausea and vomiting in patients receiving cancer chemotherapy. Oncology 59(2):100–104CrossRefPubMed

21.

Morrow GR (1986) Effect of the cognitive hierarchy in the systematic desensitization treatment of anticipatory nausea in cancer patients: a component comparison with relaxation only, counseling, and no treatment. Cogn Ther Res 10(4):421–446CrossRef

22.

Morrow GR, Asbury R, Hammon S, Dobkin P, Caruso L, Pandya K, Rosenthal S (1992) Comparing the effectiveness of behavioral treatment for chemotherapy-induced nausea and vomiting when administered by oncologists, oncology nurses, and clinical psychologists. Health Psychol 11(4):250–256CrossRefPubMed

23.

Morrow GR, Morrell C (1982) Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 307(24):1476–1480CrossRefPubMed

24.

Redd WH, Andresen GV, Minagawa RY (1982) Hypnotic control of anticipatory emesis in patients receiving cancer chemotherapy. J Consult Clin Psychol 50(1):14–19CrossRefPubMed

25.

Lugini A, Rossi R, Rauco A, Pace R, Capparella V (2012) Role of paroxetine in the treatment anticipatory nausea and vomiting in cancer patients: multicentre experience. Support Care Cancer 20:S51. doi:10.1007/s00520-012-1479-7

Title: 2016 updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy
Authors: L. Lee Dupuis
Joseph A. Roscoe
Ian Olver
Matti Aapro
Alexander Molassiotis
Publication date: 01-01-2017
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 1/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-016-3330-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Feasibility of implementing the ‘Screening for Distress and Referral Need’ process in 23 Dutch hospitals

2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents

Venous thromboembolism treatment outcomes in cancer patients and effect of third-party payers on anticoagulant choice

2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children

Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits

2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer